> Neuromed Pharmaceuticals, a biopharmaceutical company developing chronic pain drugs, announced the completion of a series D financing of $25 million. This fourth round of financing brings Neuromed's cumulative venture capital financing to $74 million. Release
> About two dozen MS sufferers made fervent pleas to an FDA committee to return Tysabri to the market. Report
> Emisphere Technologies inked a deal with Novartis worth up to $30 million in milestone payments for the use of its drug delivery technology. Report
> Ikonisys has closed a $10 million series D private equity financing round. Release
> The jury in the latest Vioxx trial got a close look at Merck documents outlining the company's concerns about the cardiovascular risks posed by the drug long before it was removed from the market. Report
> Speedel announced today that it has reached late-stage preclinical profiling of a new series of renin inhibitors designated as the SPP1100 series. Release
> Valeant Pharmaceuticals has settled a dispute with the Serbian government. Release
> FEI Company and Sweden-based Sidec Technologies today announced that the two companies will collaborate on the commercialization of Protein Tomography solutions and services based on Sidec's proprietary software and intellectual property, and FEI's transmission electron microscopes. Release
And Finally... A new study indicates that physicians' choice of chemotherapy drugs is influenced by payment methods. Article